Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 73,466 | 63,474 | 43,970 | 165,815 | 16,074 |
| Cost of Goods | 8,304 | 5,441 | 7,854 | 3,509 | 1,911 |
| Gross Profit | 65,162 | 58,033 | 36,116 | 162,306 | 14,163 |
| Operating Expenses | 56,650 | 67,744 | 49,455 | 48,031 | 59,748 |
| Operating Income | 8,816 | -9,270 | -12,485 | 114,784 | -44,674 |
| Interest Expense | 3,977 | 2,288 | 2,431 | 3,713 | 3,627 |
| Other Income | 1,712 | 880 | 890 | 2,859 | 691 |
| Pre-tax Income | 6,551 | -10,678 | -14,026 | 113,930 | -47,610 |
| Income Tax | -328 | 29 | N/A | N/A | N/A |
| Net Income Continuous | 6,879 | -10,707 | -14,416 | 113,930 | -47,610 |
| Net Income | $6,879 | $-10,707 | $-14,416 | $113,930 | $-47,610 |
| EPS Basic Total Ops | 0.05 | -0.07 | -0.09 | 0.80 | -0.34 |
| EPS Basic Continuous Ops | 0.05 | -0.07 | -0.09 | 0.80 | -0.34 |
| EPS Diluted Total Ops | 0.04 | -0.07 | -0.02 | 0.73 | -0.34 |
| EPS Diluted Continuous Ops | 0.04 | -0.07 | -0.03 | 0.73 | -0.34 |
| EPS Diluted Before Non-Recurring Items | 0.04 | -0.07 | -0.09 | N/A | N/A |
| EBITDA(a) | $7,727 | $-10,219 | $-13,287 | $115,332 | $-44,136 |